Emiliano Pasquini

Emiliano Pasquini

Auto-generated profile, based on publicly available information

Emiliano Pasquini

Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2018 in Nature
Verified
Journal Article
Closed access
PDF file
ACArianna Calcinotto
Arianna Calcinotto
CSClarissa Spataro
Clarissa Spataro
EZElena Zagato
Elena Zagato
DMDiletta Di Mitri
Diletta Di Mitri
VGVeronica Gil
Veronica Gil
AAAndrea Alimonti
Andrea Alimonti

15 January 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JCJingjing Chen
Jingjing Chen
IGIlaria Guccini
Ilaria Guccini
DMDiletta Di Mitri
Diletta Di Mitri
DBDaniela Brina
Daniela Brina
ARAjinkya Revandkar
Ajinkya Revandkar
AAAndrea Alimonti
Andrea Alimonti

1 January 2021 in Cancer Cell
Verified
Journal Article
Closed access
IGIlaria Guccini
Ilaria Guccini
ARAjinkya Revandkar
Ajinkya Revandkar
MDMariantonietta D'AMbrosio
Mariantonietta D'AMbrosio
MCManuel Colucci
Manuel Colucci
EPEmiliano Pasquini
Emiliano Pasquini
AAAndrea Alimonti
Andrea Alimonti

1 August 2009 in Gastroenterology
Verified
Journal Article
Closed access
MCMarta Colletti
Marta Colletti
Carla CICCHINICarla CICCHINI
Carla CICCHINI
Alice CONIGLIAROAlice CONIGLIARO
Alice CONIGLIARO
LSLaura Santangelo
Laura Santangelo
TATonino Alonzi
Tonino Alonzi
LALaura Amicone
Laura Amicone

12 December 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
ARAjinkya Revandkar
Ajinkya Revandkar
MPMaria Luna Perciato
Maria Luna Perciato
ATAlberto Toso
Alberto Toso
AAAbdullah Alajati
Abdullah Alajati
JCJingjing Chen
Jingjing Chen
AAAndrea Alimonti
Andrea Alimonti
Activation of NOTCH signalling is associated with advanced prostate cancer and treatment resistance in prostate cancer patients. However, the mechanism that drives NOTCH activation in prostate cancer remains still elusive. Moreover, preclinical evidence of the therapeutic efficacy of NOTCH inhibitors in prostate cancer is lacking. Here, we provide evidence that PTEN loss in prostate tumours upregulates the expression ofADAM17, thereby activating NOTCH signalling. Using prostate conditional inactivation of bothPtenandNotch1along with preclinical trials carried out inPten-null prostate conditional mouse models, we demonstrate thatPten-deficient prostate tumours are addicted to the NOTCH signalling. Importantly, we find that pharmacological inhibition of γ-secretase promotes growth arrest in bothPten-null andPten/Trp53-null prostate tumours by triggering cellular senescence. Altogether, our findings describe a novel pro-tumorigenic network that links PTEN loss to ADAM17 and NOTCH signalling, thus providing the rational for the use of γ-secretase inhibitors in advanced prostate cancer patients.

8 August 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JCJingjing Chen
Jingjing Chen
IGIlaria Guccini
Ilaria Guccini
DMDiletta Di Mitri
Diletta Di Mitri
DBDaniela Brina
Daniela Brina
ARAjinkya Revandkar
Ajinkya Revandkar
AAAndrea Alimonti
Andrea Alimonti
In the HTML version of this article initially published, the name of author Diletta Di Mitri was miscoded in the XML such that Di was included as part of the given name instead of the family name. The error has been corrected in the HTML version of the article.